Publication
PCDHGB2 promotes docetaxel resistance in prostate cancer via TR4-mediated activation of the HIF-1α/VEGFA pathway.
Fanyu Meng, Xinyi Zhou, Yong Qin, Pengju Liu
CytotechnologyOct 1, 2026PMID 42621174doi:10.1007/s10616-026-01051-2 PMC13486462Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260917-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
UNLABELLED: Prostate cancer poses a significant threat to men's health worldwide. Docetaxel (DTX) remains a cornerstone chemotherapeutic agent for PC, yet the emergence of docetaxel resistance has critically compromised clinical outcomes. Elucidating the molecular mechanisms underlying docetaxel…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.